Synergistic Effect of Parathyroid Hormone and Growth Hormone on Trabecular and Cortical Bone Formation in Hypophysectomized Rats

Background/Aims: Growth hormone (GH) deficiency in pediatric patients results in short stature and osteopenia. We postulated that the GH and parathyroid hormone (PTH) combination would result in improvement in bone growth and bone formation. Methods: Forty hypophysectomized female rats at age 8 weeks were divided into hypophysectomy (HX), HX + PTH (62.5 µg/kg, s.c. daily), HX + GH (3.33 mg/kg, s.c. daily), and HX + PTH + GH for a 4-week study. Results: GH increased body weight, bone growth, bone mineral content (BMC) and bone mineral density (BMD), whereas PTH increased BMC and BMD without a significant effect on bone size. GH increased both periosteal and endocortical bone formation and cortical size, while PTH increased only endocortical bone formation. GH mitigated the trabecular bone loss by increasing bone formation, while PTH increased bone mass by increasing bone formation and suppressing osteoclast number per bone area. The result of combined intervention shows an increase in trabecular, periosteal and endocortical bone formation and suppression of bone resorption resulting in a synergistic effect on increasing trabecular and cortical bone volume and BMD. Conclusion: The combination treatment of PTH and GH increases bone growth, bone formation, decreases bone resorption and has a synergistic effect on increasing bone density and bone mass.

[1]  J. Iwamoto,et al.  Effects of Vitamin K2 and Risedronate on Bone Formation and Resorption, Osteocyte Lacunar System, and Porosity in the Cortical Bone of Glucocorticoid-Treated Rats , 2008, Calcified Tissue International.

[2]  J. Bilezikian.  Combination anabolic and antiresorptive therapy for osteoporosis: Opening the anabolic window , 2008, Current osteoporosis reports.

[3]  W. Fraser,et al.  Effects of Growth Hormone Administration on Bone Mineral Metabolism, PTH Sensitivity and PTH Secretory Rhythm in Postmenopausal Women With Established Osteoporosis , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[4]  M. Rubin,et al.  The use of parathyroid hormone in the treatment of osteoporosis , 2007, Reviews in Endocrine and Metabolic Disorders.

[5]  J. Iwamoto,et al.  Effect of vitamin K2 and growth hormone on the long bones in hypophysectomized young rats: a bone histomorphometry study , 2006, Journal of Bone and Mineral Metabolism.

[6]  Masatsugu Horiuchi,et al.  London Radiation Symposium , 1963, Cell and tissue kinetics.

[7]  J. Reeve,et al.  Parathyroid hormone - a bone anabolic and catabolic agent. , 2005, Current opinion in pharmacology.

[8]  C. Rosen.  What's new with PTH in osteoporosis: where are we and where are we headed? , 2004, Trends in Endocrinology & Metabolism.

[9]  K. Brixen,et al.  Teriparatide (biosynthetic human parathyroid hormone 1-34): a new paradigm in the treatment of osteoporosis. , 2004, Basic & clinical pharmacology & toxicology.

[10]  Z. Hochberg,et al.  Growth hormone involvement in the regulation of tartrate-resistant acid phosphatase-positive cells that are active in cartilage and bone resorption , 1993, Calcified Tissue International.

[11]  R. Lindsay,et al.  Effects of combined and separate intermittent administration of low-dose human parathyroid hormone fragment (1–34) and 17β-estradiol on bone histomorphometry in ovariectomized rats with established osteopenia , 1992, Calcified Tissue International.

[12]  R. Bouillon,et al.  Growth Hormone and Bone Health , 2003, Hormone Research in Paediatrics.

[13]  W. Hop,et al.  Long-Term Effects of Growth Hormone Therapy on Bone Mineral Density, Body Composition, and Serum Lipid Levels in Growth Hormone Deficient Children: A 6-Year Follow-Up Study , 2002, Hormone Research in Paediatrics.

[14]  G. Saggese,et al.  Lumbar bone mineral density at final height and prevalence of fractures in treated children with GH deficiency. , 2002, The Journal of clinical endocrinology and metabolism.

[15]  J. Reginster,et al.  Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. , 2001, The New England journal of medicine.

[16]  D. Kalu,et al.  Effects of separate and combined therapy with growth hormone and parathyroid hormone on lumbar vertebral bone in aged ovariectomized osteopenic rats. , 2001, Bone.

[17]  R. Bouillon,et al.  Growth Hormone Deficiency and Peak Bone Mass , 2000, Journal of pediatric endocrinology & metabolism : JPEM.

[18]  H. Oxlund,et al.  The Influence of Combined Parathyroid Hormone and Growth Hormone Treatment on Cortical Bone in Aged Ovariectomized Rats , 2000, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[19]  J. Adachi,et al.  Histomorphometric evidence for increased bone turnover without change in cortical thickness or porosity after 2 years of cyclical hPTH(1-34) therapy in women with severe osteoporosis. , 2000, Bone.

[20]  L. Mosekilde,et al.  Parathyroid hormone and growth hormone have additive or synergetic effect when used as intervention treatment in ovariectomized rats with established osteopenia. , 2000, Bone.

[21]  R. Lindsay,et al.  Is Parathyroid Hormone a Therapeutic Option for Osteoporosis? A Review of the Clinical Evidence , 1998, Calcified Tissue International.

[22]  J. Aloia,et al.  Histologic evidence: Growth hormone completely prevents reduction in cortical bone gain and partially prevents cancellous osteopenia in the tibia of hypophysectomized rats , 1997, The Anatomical record.

[23]  L. Wilhelmsen,et al.  Increased fracture frequency in adult patients with hypopituitarism and GH deficiency. , 1997, European journal of endocrinology.

[24]  F. Melsen,et al.  The influence of growth hormone on cancellous and cortical bone of the vertebral body in aged rats , 1996, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[25]  J. Fauchère,et al.  Effects of parathyroid hormone and agonists of the adenylyl cyclase and protein kinase C pathways on bone cell proliferation. , 1996, Bone.

[26]  R. Turner,et al.  Intermittent parathyroid hormone treatment increases osteoblast number, steady state messenger ribonucleic acid levels for osteocalcin, and bone formation in tibial metaphysis of hypophysectomized female rats. , 1995, Endocrinology.

[27]  A. Scutt,et al.  The (18-48)-fragment of human parathyroid hormone is a partial agonist for cAMP-dependent actions with retained mitogenic function. , 1995, Bone.

[28]  M. Thorén,et al.  Reduced bone mineral density in adults with growth hormone (GH) deficiency: increased bone turnover during 12 months of GH substitution therapy. , 1995, European journal of endocrinology.

[29]  A. Flyvbjerg,et al.  Growth hormone stimulates bone formation and strength of cortical bone in aged rats , 1995, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[30]  T. Wronski,et al.  A comparison of the anabolic effects of parathyroid hormone at skeletal sites with moderate and severe osteopenia in aged ovariectomized rats , 1995, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[31]  W. Zhang,et al.  Effects of parathyroid hormone and estradiol on proliferation and function of human osteoblasts from fetal long bone. An in vitro study. , 1994, Chinese medical journal.

[32]  P. Lips,et al.  Consequences of childhood‐onset growth hormone deficiency for adult bone mass , 1994, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[33]  L. Mosekilde,et al.  The effect on vertebral bone mass and strength of long term treatment with antiresorptive agents (estrogen and calcitonin), human parathyroid hormone-(1-38), and combination therapy, assessed in aged ovariectomized rats. , 1994, Endocrinology.

[34]  G. Saggese,et al.  Twenty-four-Hour Osteocalcin, Carboxyterminal Propeptide of Type I Procollagen, and Aminoterminal Propeptide of Type III Procollagen Rhythms in Normal and Growth-Retarded Children , 1994, Pediatric Research.

[35]  R. Whitehouse,et al.  Reduced bone mineral density in patients with adult onset growth hormone deficiency. , 1994, The Journal of clinical endocrinology and metabolism.

[36]  J. Riond.  Modulation of the anabolic effect of synthetic human parathyroid hormone fragment-(I-34) in the bone of growing rats by variations in the dosage regimen. , 1993, Clinical science.

[37]  R. Lindsay,et al.  Loss of cancellous bone mass and connectivity in ovariectomized rats can be restored by combined treatment with parathyroid hormone and estradiol. , 1993, The Journal of clinical investigation.

[38]  R. Whitehouse,et al.  Increased bone density after recombinant human growth hormone (GH) therapy in adults with isolated GH deficiency. , 1993, The Journal of clinical endocrinology and metabolism.

[39]  T. Wronski,et al.  Parathyroid hormone is more effective than estrogen or bisphosphonates for restoration of lost bone mass in ovariectomized rats. , 1993, Endocrinology.

[40]  A. Hodsman,et al.  Early histomorphometric changes in response to parathyroid hormone therapy in osteoporosis: evidence for de novo bone formation on quiescent cancellous surfaces. , 1992, Bone.

[41]  S. Ljunghall,et al.  The bone mineral density in acquired growth hormone deficiency correlates with circulating levels of insulin‐like growth factor I , 1992, Journal of internal medicine.

[42]  Jonathan Reeve,et al.  Treatment of osteoporosis with parathyroid peptide (hPTH 1–34) and oestrogen: increase in volumetric density of iliac cancellous bone may depend on reduced trabecular spacing as well as increased thickness of packets of newly formed bone , 1992, Clinical endocrinology.

[43]  J. Kaufman,et al.  Bone mineral status in growth hormone-deficient males with isolated and multiple pituitary deficiencies of childhood onset. , 1992, The Journal of clinical endocrinology and metabolism.

[44]  R. Ziegler,et al.  [Increased prevalence of osteoporosis and arteriosclerosis in conventionally substituted anterior pituitary insufficiency: need for additional growth hormone substitution?]. , 1991, Klinische Wochenschrift.

[45]  O. Tørring,et al.  The anabolic effects of human parathyroid hormone (hPTH) on rat vertebral body mass are also reflected in the quality of bone, assessed by biomechanical testing: a comparison study between hPTH-(1-34) and hPTH-(1-84). , 1991, Endocrinology.

[46]  J. Hock,et al.  Anabolic effect of human synthetic parathyroid hormone-(1-34) depends on growth hormone. , 1990, Endocrinology.

[47]  D. Kalu,et al.  Human parathyroid hormone‐(1‐34) prevents bone loss and augments bone formation in sexually mature ovariectomized rats , 1990, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[48]  J. Hock,et al.  Human parathyroid hormone-(1-34) increases bone mass in ovariectomized and orchidectomized rats. , 1988, Endocrinology.

[49]  M. Drezner,et al.  Bone histomorphometry: Standardization of nomenclature, symbols, and units: Report of the asbmr histomorphometry nomenclature committee , 1987, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[50]  J. Jansson,et al.  Mode of action of pituitary growth hormone on target cells. , 1985, Annual review of physiology.

[51]  J Reeve,et al.  Anabolic effect of human parathyroid hormone fragment on trabecular bone in involutional osteoporosis: a multicentre trial. , 1980, British medical journal.

[52]  N. Kember.  GROWTH HORMONE AND CARTILAGE CELL DIVISION IN HYPOPHYSECTOMIZED RATS , 1971, Cell and tissue kinetics.